Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002713762 | SCV003566646 | uncertain significance | Inborn genetic diseases | 2021-07-20 | criteria provided, single submitter | clinical testing | The c.1279A>G (p.N427D) alteration is located in exon 6 (coding exon 4) of the MKKS gene. This alteration results from a A to G substitution at nucleotide position 1279, causing the asparagine (N) at amino acid position 427 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004538863 | SCV004116416 | uncertain significance | MKKS-related disorder | 2022-10-12 | criteria provided, single submitter | clinical testing | The MKKS c.1279A>G variant is predicted to result in the amino acid substitution p.Asn427Asp. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0018% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/20-10386329-T-C). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Fulgent Genetics, |
RCV005028355 | SCV005663372 | uncertain significance | McKusick-Kaufman syndrome; Bardet-Biedl syndrome 6 | 2024-02-29 | criteria provided, single submitter | clinical testing |